23andMe said it's started exploring strategic alternatives, including a possible sale.
The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
The stock, which lost 82% of its value last year, fell 10% in extended trading and was briefly halted.. Revenue in the company's consumer services business dropped 8% to $39.6 million from $42.9 million in the same period last year.
Health Care Industry Technology Breaking News: Technology 23Andme Holding Co. Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
23andMe exploring a sale of its Lemonaid telehealth businessBusiness Insider tells the global tech, finance, stock market, media, economy, lifestyle, real estate, AI and innovative stories you want to know.
Read more »
23andMe Grapples with Financial Crisis, Explores Drastic Options23andMe, the consumer genomics company known for its DNA testing kits, faces a financial crisis with a significant revenue decline. The company explores options such as a sale, restructuring, or business combination to remain viable.
Read more »
23andMe Faces Uncertain Future After Revenue Drop and Board Resignations23andMe, the consumer genomics company, announced a second consecutive quarter of 8% decline in consumer services revenue, raising concerns about its future. The company's board resigned, citing disagreements with CEO Anne Wojcicki over strategic direction. 23andMe has formed a special committee to explore options including a sale, restructuring, or business combination.
Read more »
23andMe Faces Uncertain Future with Revenue Drop and 'Substantial Doubt' About Going Concern23andMe reported an 8% year-over-year decline in consumer services revenue for the third quarter, marking the second consecutive drop. The company revealed that it may explore options such as a sale, restructuring, or business combination to secure its financial future. 23andMe stated it requires additional liquidity and is seeking capital to fund its operations. The company's valuation has plummeted to less than $100 million, down from its peak of $6 billion. In March, an independent committee was formed to evaluate the company's future, but its directors subsequently resigned due to disagreements with CEO Anne Wojcicki over the strategic direction.
Read more »
23andMe Faces Uncertain Future Amidst Financial Woes and Leadership ShakeupConsumer genetics company 23andMe struggles with declining revenue and contemplates strategic options including a sale, restructuring, or business combination. The company's CEO faces pressure from the board and explores ways to ensure its long-term survival.
Read more »
Adrian Dittman, Grilled In Wild ‘Fortnite’ Stream, Is Likely Not Elon Musk’s Alter EgoConnorEatsPants invited “Adrian Dittman” on his weekly Fortnite Friday comedy stream, and Dittman accepted, playing Fortnite with him for several hours.
Read more »